

Amendments to the Claims:

The following listing of claims will replace all prior versions and listings of claims.

Listing of Claims

- 1-20. (canceled)
21. (currently amended) An immunoassay method, comprising:
 - (a) contacting a sample with an antibody or fragment thereof that binds a polypeptide consisting of ~~at least 30 contiguous~~ amino acid residues 1 to 303 of SEQ ID NO:2; and
 - (b) detecting binding of polypeptides from said sample to said antibody.
22. (previously presented) An immunoassay method according to claim 21, wherein said assay is selected from the group consisting of a radioimmunoassay, a competitive-binding assay, a Western blot analysis and an ELISA assay.
23. (currently amended) An immunoassay method according to claim 21, wherein said assay is a competitive-binding assay and wherein said antibody or fragment thereof is bound to a solid support.
24. (currently amended) An immunoassay method according to claim 21, wherein said detecting step comprises generating a signal from a reporter antibody that binds said antibody or fragment thereof that binds a polypeptide consisting of amino acid residues 1 to 303 of SEQ ID NO:2, wherein to which a detectable reagent is attached to said reporter antibody.
25. (previously presented) An immunoassay method according to claim 24, wherein said detectable reagent is comprises a radiolabel, a fluorescent label, or an enzyme label.
26. (previously presented) An immunoassay method according to claim 21, wherein said antibody is a monoclonal antibody.
27. (previously presented) An immunoassay method according to claim 21, wherein said antibody is a polyclonal antibody.

28. (previously presented) An immunoassay method according to claim 21, wherein said antibody is a chimeric antibody.
29. (currently amended) An immunoassay method according to claim 2426, wherein said antibody is a human antibody.
30. (previously presented) An immunoassay method according to claim 21, wherein said antibody is a single chain antibody.
31. (previously presented) An immunoassay method according to claim 21, wherein said antibody is an Fab fragment.
- 32-33. (canceled)
34. (currently amended) An immunoassay method according to claim 21, further comprising comparing the results obtained from said detecting step to a standard curve to determine the amount of protein present in a given volume of said ~~tissue~~ sample.
35. (previously presented) An immunoassay method according to claim 21, wherein said sample is a tissue sample obtained from a patient.